Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations |
| |
| Authors: | Bonnie P. Hersh MD Nancy L. Earl MD Robert A. Hauser MD Mark Stacy MD |
| |
| Affiliation: | 1. Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts, USA;2. Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina, USA;3. Department of Neurology, University of South Florida, Tampa, Florida, USA;4. Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina, USA |
| |
| Abstract: | ![]()
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society |
| |
| Keywords: | efficacy motor fluctuations Parkinson's disease ropinirole prolonged release Unified Parkinson's Disease Rating Scale |
|
|
